Why the study?
Does doxorubicin treatment cause late cardiotoxicity in long-term survivors of malignant bone tumors?
Population
31 long-term survivors of malignant bone tumors treated with Rosen's T5 or T10 protocol, age 10-45 years.
Design
Cohort
Follow-up
2.3-14.1 years following completion of treatment
Authors
Loading...
Supports lifelong cardiac surveillance in these survivors; leaves open causality and optimal strategies.
Does doxorubicin treatment cause late cardiotoxicity in long-term survivors of malignant bone tumors?
Long-term survivors of malignant bone tumors treated with doxorubicin have a high incidence of late cardiotoxicity that increases over time, highlighting the need for life-long cardiac follow-up.
Postma et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: